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Context: Complementary and alternative medicines (CAMs) are increasingly being
utilized in the pediatric cancer population, despite unproven risks and benefits, and
significant additional cost of treatment.
Objective: To identify the prevalence of CAM use and the most frequently utilized CAMs,
and to examine the physiologic impact of CAM in pediatric cancer patients undergoing
chemotherapy. Additional objectives included identifying the cost associated with CAM,
and the rationale for CAM usage.
Design: Cross‐sectional study of 40 children, between 2 to 18, diagnosed with a
malignancy of any kind between 2000 and 2008. Families completed a survey, including
questions on demographics, utilization of CAMs, and any associated costs. Chart review
was performed and Absolute Neutrophil Count (ANC) was trended during CAM use.
Categorical data were analyzed using a Pearson’s Chi‐square test with Fischer Exact Test.
Student’s t test was performed to evaluate association between CAM and ANC.
Results: The prevalence of CAM usage in our population was 54%. Patients frequently
used anti‐oxidant vitamins and minerals for prevention of further illness 72.7%
(p=0.001), and frequently used herbs and herbal teas for relief from treatment‐related
symptoms 83.3% (p=0.004). Lower ANCs were found in patients using immune
modulating juices (ANC average 1542, p=0.025) when compared to all other groups.
Finally, 70% of patients and families spent between $25‐120/month on CAM treatment.
Conclusion: CAM use is prevalent among pediatric cancer patients and is used primarily
for alleviation of treatment related side‐effects and augmentation of immune status.
However, there is considerable cost associated with treatment, and some therapies may
be associated with lower absolute neutrophil counts during treatment.
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Introduction
Complementary and alternative medicines (CAM) have been increasingly utilized in the
treatment of children with cancer during the past three decades.1,2,3,4, 5 CAMs
encompass broad treatment categories, ranging from ingested botanical agents, to
massage and acupuncture, and even include prayer and spiritual practices.6, 7 By
definition, CAMs have scientifically unproven risks and benefits, yet patients are
compelled to use them for a multitude of reasons.8,9 Several factors make CAM use
compelling. CAMs carry the designation of being derived from a ‘natural’ substance, and
consequently are assumed to be safe.2 Many CAMs are far less expensive than FDA‐
approved drugs, do not require a prescription, and therefore offer patients a greater
degree of autonomy in using them for treatment effects . When a child is faced with
cancer, parents sometimes provide CAMs to their children with the justification that
‘everything possible is being done’ to achieve a cure for their child. 10,11 Not surprisingly,
many patients and their families utilize CAMs but do not disclose CAM usage to their
physician, because they perceive that these therapies are not ‘drugs’ or because they
fear reproach from healthcare personnel because such practices may be viewed as a
form of non‐compliance.6, 12 Nevertheless, many CAMs have pharmacobiological
activities that may cause serious adverse drug events or drug‐drug interactions.
Despite the abundance of available CAM therapies and the prevalence of CAM
usage, CAM therapies are not well regulated. Concentrations of active ingredients can
vary greatly from product to product, a practice that can obscure the true incidence of
specific side‐effects. 13 While most CAMs are not associated with toxicities, several have
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been associated with serious adverse events that have lead to bleeding disorders,
hypertensive crisis, and coronary ischemia. Even simple herbal infusions have been
linked to fatal gastroenteric, hepatic, and nephrotoxic episodes. 14, 15, 16 Other herbal
preparations contain high levels of contaminants such heavy metals, fungus, and
bacteria. 17,18 Less obvious to the cancer patient are instances where CAMs may result in
up‐regulation of CYP3A4, resulting in chemotherapy inactivation, or may enhance the
expression of ATPase Binding Cassette (ABC) protein‐mediated drug efflux, leading to
reduced anti‐cancer effects.19,20,21,22, 23
Recent investigations have shown that anti‐oxidant supplements can attenuate
the cytotoxic effects of cylcophosphamide, vincristine, methotrexate, and cytarabine;
drugs which derive at least part of their effect by generating reactive oxygen species.24
Used in conjunction with these agents, high‐dose vitamins, minerals, and related CAMs
may limit the ability of drugs that are commonly used to treat pediatric malignancies.25
By reducing the effectiveness of cytotoxic therapy against cancer cells, these CAMs may
lead, in theory, to relapse as a serious adverse event.26, 27, 28, 29, 30,31 On the other hand,
CAMs that diminish myelosuppresion, mucositis, and chemotherapy‐associated cachexia
might enhance a patient’s compliance with FDA‐approved chemotherapeutic agents.
A number of studies have assessed CAM use in children with cancer, and have
shown that despite the prevalence of CAM use in the pediatric cancer population, it is
still unclear whether these therapies deserve a place in the treatment of cancer.32 This
fact is important when considered alongside of the economic burdens associated with
CAM use, which may total up to $250/year for therapies which may have limited or even
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deleterious impact on overall disease course.33,34 While a number of studies have
provided important insights into the use of CAMs for children receiving chemotherapy,
it remains unclear whether correlations exist between chemotherapy‐associated
toxicities and specific CAM selection, precise costs associated with CAM use, or whether
CAM usage might impact hematopoietic function. To address these concerns, we
performed a cross‐sectional survey of a population of patients at the University of New
Mexico. We found that CAMs were frequently utilized in our pediatric cancer
population, and were associated with a significant impact on a number of biological and
economic outcomes associated with a cancer treatment course.
Patients and Methods and Survey Instrument
We performed a cross‐sectional study of 40 children and young adults who were
between the ages of 2‐19 and diagnosed with a malignancy of any kind between 2000
and 2008. Inclusion criteria included the provision of written, informed consent in
accordance of institutional guidelines (HRRC #07‐131) and had a parent who could
read/speak English, or who could themselves (if 17 years of age or older) read/speak
English. Patients were treated on a variety of studies sponsored by the Children’s
Oncology Group, or as supported in the written literature as best clinical practice. Study
participants received cancer treatment for a minimum of 8 weeks before being recruited
for participation in a short survey (see Appendix I). Our 10 question survey included
questions regarding demographic data, utilization of CAM, and in relevant patients, the
costs associated with CAM use. For the purposes of a chart review, all patients were
assigned a unique identification number.
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Stratification and Chart Review
Data were stratified based on reported CAM usage (use vs. non‐use), type of
cancer, and age (0‐4 yrs, 5‐11 yrs, 12‐18 yrs) if applicable. For correlative purposes, in
patients having acute lymphoblastic leukemia, all annotated data was correlated with
mean absolute neutrophil counts (ANC) during maintenance phase of therapy. In order
to adjust for differences in age, diagnosis/stage, and use of cytokine stimulation, the
ANC was recorded for each patient at the start of treatment then every two weeks until
the first 8 weeks of chemotherapy had been completed. Subsequently, data from
patients who continued to receive cytokine treatment was collected on a monthly basis
± 2 days until the end of treatment.
Statistical Methods and Data Analysis
To facilitate uniform statistical interpretation the study team created five categorical
designations into which each CAM Therapy could be assigned (Table 1). The categories
were based upon 1) type of modality and 2) proposed mechanism of action of that
therapy. Statistical analyses were performed to compare prevalence of CAM use
according to type of modality. Categorical data were analyzed using a Pearson’s Chi‐
square test with Fischer Exact Test for data sets where 1/5th or more of the cells of a
table were sparsely populated (cell value < 5). Alpha was set at P ≤ 0.05. Likewise,
Pearson Chi‐square test was used to evaluate potential associations between Reasons
for Use and Costs. To evaluate relationships between CAM usage according to age and
the Absolute Neutrophil Count (ANC), Student’s t test were performed.
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Results
Over the course of 18 months, we identified 40 patients who responded to our survey
questionnaire. Among the patients studied, 62% were boys and 38% were girls who
were affected by a variety of cancers (Table 1). Ages ranged from 2 to 18 years of age.
Based on responses to the survey, questions, 39 were eligible for complete analysis.
Four of the 39 patients did not complete the sections of the survey specifying type of
CAM modality and associated costs, and were therefore excluded from those respective
portions of the data analysis. The remaining 35 were eligible for Absolute Neutrophil
Count (ANC) comparison based upon 1) assenting to ANC review and 2) presence of
complete medical records.
Approximately 54% of all respondents reported CAM use during at least a one‐
month period during their cancer treatment. As a consequence of our finding, a high
prevalence of CAM usage in our patient population, we next investigated which
substances were most commonly used and the justifications for their use (Figure 1).
Multiple respondents (n=6) used more than one CAM modality. In these instances, we
analyzed multiple CAM exposures as separate incidences. The most frequently cited
reasons for CAM use by patients, in descending order of occurrence, were to prevent
further illness, to relieve treatment‐related toxicities, and to provide relief from cancer‐
related symptoms.
Our survey results revealed that most botanical CAMs possessed known anti‐
oxidant effects. In addition, a number of respondents cited using minerals, immune
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modulating juices, herbs and herbal teas, which have also been reported to have anti‐
oxidant effects.24‐31 Therefore, we next sought to identify potential correlations linking
botanical CAM agents with the reasons why patients used them. We found statistically
significant correlations between anti‐oxidant vitamin and mineral use in patients who
used this class of CAM for the relief of treatment‐related symptoms (Chi‐Square Test
p=0.041) and for prevention of further illness (p=0.001; Table 3). Furthermore, we found
that the use of herbs and herbal teas were strongly correlated with our respondents
who used CAMs to relieve cancer‐treatment related symptoms (p=0.004). Among the
CAMs identified in our survey, we found a trend among respondents to utilize herbs and
herbal teas to alleviate cancer‐related symptoms. Moreover, we note a trend to use
immune‐modulating juices to prevent further illness (p=0.063). We found no statistical
correlation with regard to use of CAM for specific cancer diagnosis or with age.
CAMs have been predicted to neutralize the effects of anti‐cancer therapy, and
therefore in theory might increase the risk of relapse. Based on the investigations of
Weijl et al. and others, we hypothesized that CAM would rescue patients from the
effects of anti‐metabolite‐based therapy directed against ALL and other pediatric
cancers. while there were clear statistical associations between reason for use and
selection of CAM modality, there was no statistical correlation demonstrated with
regard to use of CAM based upon the type of cancer diagnosis, i.e. leukemia and
lymphoma vs. all soft‐tissue tumors. Moreover, there was no statistical correlation with
regard to the subtype of CAM and diagnosis. Finally, there was no statistical correlation
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with regard to age and use of a CAM, nor subtype of CAM modalities and age set
(grouped as 0‐4, 5‐11, 12‐18 years of age).
Based on the investigations of Weijl et al. and others, we hypothesized that CAM
would increase Absolute Neutrophil Counts in pediatric cancer patients due to the
rescuing effects of anti‐oxidants.24‐26 We collected data related to ANCs in CAM and
non‐CAM users, as the neutrophil count is used to intensify or de‐intensify therapy in
the maintenance phase of a number of ALL studies. While we found no statistical
difference in ANCs between CAM users and non‐users, we found a trend between low
ANC and the utilization of immune‐modulating juices in our respondents who used
CAMs.
To better understand the economic burden of CAM usage, we next assessed
costs associated with their use. We found 23.5% reported spending between $1‐5 per
week, 32.5% spent between $6‐10 per week, 17.6% spent between $21‐30 per week,
and another 23.5% reported spending in excess of $30 per week. Among specific
subcategories of CAM users, 72.6% of those utilizing Anti‐Oxidants and Minerals spent
between $6‐20 each week. For patients and their families using immune modulating
juices, 66.6% reported spending >$30 each week. Despite these costs, 21 of 27
respondents (77.7%) indicated an interest in learning more about CAM. These responses
were often accompanied by personal annotations suggesting an interest in the topic
(see Discussion). Interestingly, 38% of respondents who wished to learn more about
CAMs reported that they had not used CAMs in treatment of themselves/their child
during cancer treatment course.
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Discussion
Dose‐intensified multi‐agent therapy has achieved considerable increases in survival
rates for children and young adults who are treated for cancer. While often forgotten or
not assessed, patients and their families often rely upon CAMs to help them through a
treatment course.3‐8,10 Because of the frequency which CAM use has previously been
demonstrated, and because CAMs can affect chemotherapy, we assessed CAM usage in
a single‐institution study. In our survey of 40 patients, we found that CAM was utilized
by over half of our respondents. We discovered that patients and their families utilized
anti‐oxidants, vitamins and minerals, and herbs/herbal infusions to control treatment‐
related symptoms and to prevent additional treatment‐related toxicities. Despite the
unproven risks and benefits of CAMs, we also found that patients and their families
were willing to spend more than $500 annually for these products. We were surprised
to find that, in contrast to our initial hypothesis, patients using immune modulating
juices had a comparatively lower mean ANC than non‐CAM users when receiving
maintenance treatment for childhood cancer. Our results call for further investigation
into the use, patient/parental justification, and biological effects of CAM among children
and young adults who face a cancer diagnosis.
We found that more than half of our patients reported using CAMs in one form
or another. In agreement with our results, Sencer, Kelly, and others3‐5 reported CAM
usage between 36 and 84% in their studies of pediatric cancer patients.
We found that Anti‐Oxidant Vitamins and Minerals and Herbs and Herbal Teas
were used most frequently in childhood cancer patients. Our results differed from the
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results of Post‐White et al. who reported that the prayer was the most frequently used
modality in this population (69.4%) followed by massage, vitamins, and supplement use.
The primary reasons for CAM utilization in our study were for the relief of treatment‐
related symptoms as well as prevention of additional toxicities. While other studies
including that of Post‐White have similarly found that the primary reason for CAM use
was to manage side effects, secondary reasons for CAM use in other studies included
feeling more hopeful and coping with emotional effects of cancer. Our results suggest
that patients and families are using CAM not to treat cancer itself, nor to bolster
emotional well‐being, but to ameliorate the various side‐effects of chemotherapy and to
mitigate the risk of neutropenic illness.
The most interesting finding of this study was the impact of CAM on absolute
neutrophil count. We had originally hypothesized that CAM would rescue the effects of
chemotherapy, thereby increasing ANC. In contrast, we found that those using immune‐
modulating juices had lower mean ANCs when compared to both non‐CAM users and all
other CAM users (Table 3). The difference in absolute neutrophil count (<1.0x103) does
not appear clinically significant; however this can’t be substantiated without
longitudinal data collection. We hypothesize that this correlation may reflect that this
patient subset initially had low ANCs. Given relatively low ANC values, families may have
elected to seek alternative methods for boosting neutrophil counts to help their
children avoid neutropenic illness. This hypothesis is corroborated by the fact that these
patients were more likely to use immune‐modulating juices to prevent further illness
(Table 3). Among other CAM categories, there was no significant difference in ANC when
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compared with non‐CAM users. These data suggest that the medical community should
seek to identify how complementary and alternative medicines may interact with
chemotherapeutic regimens.
Cost associated with CAM use was similar to that noted by Kligler, Sapna,
Alsawaf, and Jatoi, however when data were extrapolated over the course of a year or
over the course of treatment, costs were substantially higher.35 The specific types of
CAM utilized and the reasons for utilization were different from those reported by Post‐
White et al. and Cheung et al..35,36 Our results suggest further investigation into the role
of CAM as an adjunctive treatment in cancer. We next investigated the cost associated
with CAM usage. We demonstrated that 76.5% of patients who use CAMs can spend
between $24 and $100+ a month. This average is more than twice the mean of $27
previously suggested Alsawaf and Jatoi. When our data is extrapolated over the course
of one year, patients may spend between $300 and $1500. If families elect to use the
same CAM throughout the duration of treatment, some families may spend close to
$4000 for complementary and alternative therapies. These data are significant given the
prevalence, cost, and unknown effects of CAM use. Further study is warranted to assess
the cost/benefit outcomes in of CAM use childhood cancer patients over the course of
treatment. An overwhelming three‐quarters of patients or patients’ families wanted
more information on CAM, even if they denied current CAM use. Among the subjective
responses of patients and families were:
I’m glad this study is happening.
We would want to see more CAM added to chemo regimens.
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What [other] therapies could be used?
I hope in the future that CAM will be part of the Chemo treatment.
Future Directions
Complementary therapies are frequently being utilized in the treatment of cancer
despite the high cost associated with these therapies. Moreover, CAM seems to have a
physiologically important role in cancer patients. Therefore, future investigations would
be invaluable in establishing: 1) What impact CAM has on cancer and cancer treatment?
2) Does the use of immune modulating juices impact hematopoiesis resulting in lower
ANCs or are these juices harmless but costly adjunctive treatments? Finally, because
CAM use 1) is prevalent 2) is frequently not disclosed to physicians and 3) possibly
mitigates chemotherapeutic treatment, is CAM use a form of non‐compliance?
Secondly, Spanish‐speaking only families were not approached for participation
in the study, primarily because the researchers could not have the survey or consent
forms translated in time, nor could researchers explain, in full‐detail the purpose and
extent of the study. The exclusion of this population may have artificially decreased
reported CAM usage, as these patients often use traditional folk practices including
usage of alternative medicines from curanderos (healers) and yerberos (herbalists)
alongside of traditional medical practices. In a study conducted in South Texas, with a
population demographic similar to that in this metropolitan area, 58% of surveyed adult
patients where using CAM.37,38 It would be beneficial to include this patient population
in the future to fully assess 1) what percentage of this population is using CAM 2) what
CAMs this population is using and 3) if they are different from mainstream CAMs.
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